1. Value Every Moment: Remember, a single minute lost to procrastination can erase the progress of a month's hard work and discipline. Stay focused and make every moment count. 2. Wealth's Silent Power: True wealth isn't about flaunting riches; it's about multiplying them. Rich individuals understand that real success comes from wisely investing their resources, making each dollar work for them. 3. The Dream of Passive Income: Imagine the ultimate flex: earning money while you sleep. It's the dream of financial independence that drives many to seek passive income streams, where your money does the heavy lifting. 4. Quiet Victories Speak Loudest: Winning isn't always about showing off. Sometimes, the most meaningful victories happen in private, away from the spotlight. Not everyone needs to witness your journey; focus on your own growth. 5. Choose Your Circle Wisely: Surround yourself with like-minded friends who inspire and push you to be your best. The company
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system; the cancer cells may even spread from the prostate to other parts of the body, making prostate cancer a very dangerous sickness.
However, a new study has found a 98.6 percent cure rate.
The study was conducted by researchers from UT Southwestern Medical Center.
They found the cure in a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target. It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.
According to Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study: “The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,
“What we now have is a more potent and effective form of completely noninvasive treatment for prostate cancer, conveniently completed in five treatments.”
Conventional treatment options for early stage prostate cancer include:
Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;
Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room. Once implanted, the seeds release their radioactivity directly into the prostate gland; and
External beam radiation, which involves 42 to 45 treatments administered over two or more months, five days a week.
“The current form of radiation is 44 treatments given over nine weeks. In contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,” said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology. “SBRT is both more convenient and has increased potency.”
UT Southwestern served as the lead site for the multi-institutional clinical trial, which involved first-time prostate cancer patients diagnosed with stage I or stage II (low and intermediate risk) prostate cancer. A total of 91 patients were treated prospectively and followed for five years, with only one patient experiencing a recurrence of his cancer.
The findings are published in the
European Journal of Cancer.
However, a new study has found a 98.6 percent cure rate.
The study was conducted by researchers from UT Southwestern Medical Center.
They found the cure in a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target. It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.
According to Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study: “The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,
“What we now have is a more potent and effective form of completely noninvasive treatment for prostate cancer, conveniently completed in five treatments.”
Conventional treatment options for early stage prostate cancer include:
Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;
Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room. Once implanted, the seeds release their radioactivity directly into the prostate gland; and
External beam radiation, which involves 42 to 45 treatments administered over two or more months, five days a week.
“The current form of radiation is 44 treatments given over nine weeks. In contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,” said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology. “SBRT is both more convenient and has increased potency.”
UT Southwestern served as the lead site for the multi-institutional clinical trial, which involved first-time prostate cancer patients diagnosed with stage I or stage II (low and intermediate risk) prostate cancer. A total of 91 patients were treated prospectively and followed for five years, with only one patient experiencing a recurrence of his cancer.
The findings are published in the
European Journal of Cancer.
Comments